好色先生

好色先生

Explore the latest content from across our publications
Join The AAN

Log In

Forgot Password?
Create New Account

Loading... please wait

Abstract Details

Discovery Proteomics Using Data Independent Acquisition-based Mass Spectrometry Nominate Biomarker Candidates of Atrial Fibrillation in Stroke
Cerebrovascular Disease and Interventional Neurology
P4 - Poster Session 4 (8:00 AM-9:00 AM)
5-016
To identify a plasma biomarkers signature that discriminates between IS/TIA patients with and without a history of AFib using quantitative proteomics.

Atrial fibrillation (AFib) is a major risk factor for ischemic stroke (IS), and its early diagnosis is critical to optimize secondary prevention and reduce recurrent stroke risk.
We used clinical and proteomics data of stroke patients in a prospective plasma repository (2014–2023, Yale University). Samples were collected within 24 hours of stroke onset. Plasma was depleted using High-Select Top 14 Protein Depletion Resin. We measured differentially abundant proteins (DAPs) between patients with and without AFib using data-independent acquisition-based mass spectrometry (DIA-MS). DIA-MS data were quantified using DIA-NN, log2 transformed, batch corrected using Combat function (sva package in R), imputed for peptides with ≤30% missing values using Perseus, and normalized by total area sum. DAPs were identified using ±1.5-fold change and p-value <0.05 (Welch’s t-test). We adjusted for clinical covariates in multivariable logistic regression. Regularized LASSO logistic regression was applied to identify a panel that discriminates AFib from no AFib, with its performance evaluated by 10-fold cross-validated receiver operating characteristic curves. Pathway analysis was conducted using clusterProfiler package.

Among 40 IS/TIA patients (mean age 68.7 years, 62.5% male), 14 had AFib and 26 had no AFib. DIA-MS quantified 19771 protein peptides, of which 7153 were analyzed after imputation. We identified 174 DAPs, and 63 remained significantly associated with AFib after adjustment for age, sex, and coronary artery disease (adjusted p < 0.05). LASSO regression identified a panel of 8 protein peptides that distinguished AFib from no AFib (cvAUC: 0.83, sensitivity: 71%, specificity: 85%). Pathways associated with coagulation and hemostasis were upregulated in AFib.

Our study highlights the potential of plasma proteomics as a valuable tool for discovering protein biomarkers to discriminate IS/TIA patients with AFib compared to no AFib.
Authors/Disclosures
Wooyoung Jang, PhD
PRESENTER 		Dr. jang has nothing to disclose.
Shubham Misra, PhD (Yale University) Dr. Misra has nothing to disclose.
Sebastian Sanchez Herrera, MD Sebastian Sanchez Herrera has nothing to disclose.
Victor M. Torres-Lopez, MA (Yale University) Mr. Torres-Lopez has nothing to disclose.
Pinar Caglayan Ms. Caglayan has nothing to disclose.
Richa Sharma, MD (Massachusetts General Hospital, Brigham, Harvard) Dr. Sharma has received research support from NIH. Dr. Sharma has received intellectual property interests from a discovery or technology relating to health care.
Guido J. Falcone, MD (Yale School of Medicine) The institution of Dr. Falcone has received research support from NIH. The institution of Dr. Falcone has received research support from AHA.
Lauren H. Sansing, MD Dr. Sansing has nothing to disclose.
Srikant Rangaraju, MBBS (Emory University, Atlanta) Dr. Rangaraju has nothing to disclose.